Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 6153-6158, December 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gliniak, B.
Right arrow Articles by Le, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gliniak, B.
Right arrow Articles by Le, T.
[Cancer Research 59, 6153-6158, December 15, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Tumor Necrosis Factor-related Apoptosis-inducing Ligand’s Antitumor Activity in Vivo Is Enhanced by the Chemotherapeutic Agent CPT-11

Brian Gliniak1 and Tiep Le

Department of Molecular Immunology, Immunex Corp., Seattle, Washington 98101

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in a wide variety of transformed human cells in vitro. In this study, the antitumor activity of recombinant TRAIL was analyzed in mice bearing human colon carcinoma tumors. We found that these tumors displayed a differential sensitivity to TRAIL in vivo that paralleled their susceptibility to TRAIL-induced apoptosis in vitro. Treatment of TRAIL-sensitive tumors 3 days after tumor challenge resulted in a dose-dependent inhibition of growth and the elimination of tumors in many mice. Colon carcinoma cell lines could be further sensitized to TRAIL-induced apoptosis in vitro by the addition of the chemotherapeutic agent camptothecin. Moreover, the combination of TRAIL and CPT-11, a water-soluble analogue of camptothecin, greatly enhanced the antitumor activity of TRAIL in vivo. TRAIL plus CPT-11 treatment of both 3- and 10-day established TRAIL-sensitive tumors resulted in both a significant inhibition of tumor growth and a high proportion of complete tumor regressions. Treatment of TRAIL-resistant tumors with TRAIL and CPT-11 dramatically slowed tumor growth and induced a transient tumor regression. These data demonstrate that TRAIL alone is a potent antitumor agent in vivo, and its activity can be significantly enhanced in combination with the chemotherapeutic agent CPT-11.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
I. Zinonos, A. Labrinidis, M. Lee, V. Liapis, S. Hay, V. Ponomarev, P. Diamond, A. C.W. Zannettino, D. M. Findlay, and A. Evdokiou
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
Mol. Cancer Ther., October 1, 2009; 8(10): 2969 - 2980.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. FRESE, A. SCHULLER, M. FRESE-SCHAPER, M. GUGGER, and R. A. SCHMID
Cytotoxic Effects of Camptothecin and Cisplatin Combined with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2L/TRAIL) in a Model of Primary Culture of Non-small Cell Lung Cancer
Anticancer Res, August 1, 2009; 29(8): 2905 - 2911.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al.
Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
Clin. Cancer Res., March 15, 2009; 15(6): 1998 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, N. Giuliani, L. Mazzera, G. Lombardi, M. Ricca, A. Corradi, A. M. Cantoni, L. Salvatore, R. Riccioni, A. Costanzo, et al.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways
Blood, September 15, 2008; 112(6): 2450 - 2462.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ashkenazi, P. Holland, and S. G. Eckhardt
Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
J. Clin. Oncol., July 20, 2008; 26(21): 3621 - 3630.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Cao, P. Du, S.-H. Jiang, G.-H. Jin, Q.-L. Huang, and Z.-C. Hua
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
Mol. Cancer Ther., April 1, 2008; 7(4): 851 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Li, H. Wang, Z. Wang, S. Makhija, D. Buchsbaum, A. LoBuglio, R. Kimberly, and T. Zhou
Inducible Resistance of Tumor Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2-Mediated Apoptosis by Generation of a Blockade at the Death Domain Function.
Cancer Res., September 1, 2006; 66(17): 8520 - 8528.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Matsubara, Y. Mizutani, F. Hongo, H. Nakanishi, Y. Kimura, S. Ushijima, A. Kawauchi, T. Tamura, T. Sakata, and T. Miki
Gene therapy with TRAIL against renal cell carcinoma.
Mol. Cancer Ther., September 1, 2006; 5(9): 2165 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Dong, L. Wang, J. J. Davis, W. Hu, L. Zhang, W. Guo, F. Teraishi, L. Ji, and B. Fang
Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-{alpha}-Related Apoptosis-Inducing Ligand-Armed Oncolytic Adenovirus
Clin. Cancer Res., September 1, 2006; 12(17): 5224 - 5230.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Frese, M. Frese-Schaper, A.-C. Andres, D. Miescher, B. Zumkehr, and R. A. Schmid
Cardiac Glycosides Initiate Apo2L/TRAIL-Induced Apoptosis in Non-Small Cell Lung Cancer Cells by Up-regulation of Death Receptors 4 and 5
Cancer Res., June 1, 2006; 66(11): 5867 - 5874.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Thai, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou
Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Cancer Res., May 15, 2006; 66(10): 5363 - 5370.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. Sohn, G. Totzke, F. Essmann, K. Schulze-Osthoff, B. Levkau, and R. U. Janicke
The proteasome is required for rapid initiation of death receptor-induced apoptosis.
Mol. Cell. Biol., March 1, 2006; 26(5): 1967 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. D. Zhang, J. J. Wu, S. Gillespie, J. Borrow, and P. Hersey
Human Melanoma Cells Selected for Resistance to Apoptosis by Prolonged Exposure to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Are More Vulnerable to Necrotic Cell Death Induced by Cisplatin
Clin. Cancer Res., February 15, 2006; 12(4): 1355 - 1364.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Clancy, K. Mruk, K. Archer, M. Woelfel, J. Mongkolsapaya, G. Screaton, M. J. Lenardo, and F. K.-M. Chan
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis
PNAS, December 13, 2005; 102(50): 18099 - 18104.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
Mol. Cancer Ther., December 1, 2005; 4(12): 2026 - 2036.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Voelkel-Johnson, Y. A. Hannun, and A. El-Zawahry
Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein
Mol. Cancer Ther., September 1, 2005; 4(9): 1320 - 1327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Cohen, R. B. Cohen, and N. J. Meropol
Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep
J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Minderman, J. M. Conroy, K. L. O'Loughlin, D. McQuaid, P. Quinn, S. Li, L. Pendyala, N. J. Nowak, and M. R. Baer
In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells
Mol. Cancer Ther., June 1, 2005; 4(6): 885 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. Shao, D.-F. Lee, Y. Wen, Y. Ding, W. Xia, B. Ping, H. Yagita, B. Spohn, and M.-C. Hung
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation
Mol. Cancer Res., April 1, 2005; 3(4): 219 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Matsuda, A. Almasan, M. Tomita, J.-n. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta, and N. Mori
Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines
J. Virol., February 1, 2005; 79(3): 1367 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Malathi, J. M. Paranjape, R. Ganapathi, and R. H. Silverman
HPC1/RNASEL Mediates Apoptosis of Prostate Cancer Cells Treated with 2',5'-Oligoadenylates, Topoisomerase I Inhibitors, and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
Cancer Res., December 15, 2004; 64(24): 9144 - 9151.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall
Interferon {gamma} Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma
Cancer Res., November 15, 2004; 64(22): 8349 - 8356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Izeradjene, L. Douglas, A. Delaney, and J. A. Houghton
Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6650 - 6660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Jin, R. Yang, S. Fong, K. Totpal, D. Lawrence, Z. Zheng, J. Ross, H. Koeppen, R. Schwall, and A. Ashkenazi
Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
Cancer Res., July 15, 2004; 64(14): 4900 - 4905.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Deeb, H. Jiang, X. Gao, M. S. Hafner, H. Wong, G. Divine, R. A. Chapman, S. A. Dulchavsky, and S. C. Gautam
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-{kappa}B through suppression of I{kappa}B{alpha} phosphorylation
Mol. Cancer Ther., July 1, 2004; 3(7): 803 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Shah, C.-H. Tung, K. Yang, R. Weissleder, and X. O. Breakefield
Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy
Cancer Res., May 1, 2004; 64(9): 3236 - 3242.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Chawla-Sarkar, J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden, and D. J. Lindner
Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL
J. Biol. Chem., October 10, 2003; 278(41): 39461 - 39469.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio
Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model
Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ray and A. Almasan
Apoptosis Induction in Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11
Cancer Res., August 1, 2003; 63(15): 4713 - 4723.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Liu, S. Hilsenbeck, and Y. Gazitt
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
Blood, May 15, 2003; 101(10): 4078 - 4087.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J.-P. Herbeuval, C. Lambert, O. Sabido, M. Cottier, P. Fournel, M. Dy, and C. Genin
Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis
J Natl Cancer Inst, April 16, 2003; 95(8): 611 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
V. Hietakangas, M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
Mol. Cell. Biol., February 15, 2003; 23(4): 1278 - 1291.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Leverkus, M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E.-B. Brocker, M. Goebeler, M. Neumann, and H. Walczak
Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation
Mol. Cell. Biol., February 1, 2003; 23(3): 777 - 790.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. Strater, U. Hinz, H. Walczak, G. Mechtersheimer, K. Koretz, C. Herfarth, P. Moller, and T. Lehnert
Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter
Clin. Cancer Res., December 1, 2002; 8(12): 3734 - 3740.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Naka, K. Sugamura, B. L. Hylander, M. B. Widmer, Y. M. Rustum, and E. A. Repasky
Effects of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Alone and in Combination with Chemotherapeutic Agents on Patients' Colon Tumors Grown in SCID Mice
Cancer Res., October 15, 2002; 62(20): 5800 - 5806.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib
Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-{alpha} on APO2L/TRAIL Expression and -Mediated Cytotoxicity
J. Immunol., July 15, 2002; 169(2): 809 - 817.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Chawla-Sarkar, D. W. Leaman, B. S. Jacobs, and E. C. Borden
IFN-{beta} Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis
J. Immunol., July 15, 2002; 169(2): 847 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. S. Griffith, J. M. Fialkov, D. L. Scott, T. Azuhata, R. D. Williams, N. R. Wall, D. C. Altieri, and A. D. Sandler
Induction and Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand-mediated Apoptosis in Renal Cell Carcinoma
Cancer Res., June 1, 2002; 62(11): 3093 - 3099.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Frese, T. Brunner, M. Gugger, A. Uduehi, and R. A. Schmid
Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 168 - 174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Jazirehi, C.-P. Ng, X.-H. Gan, G. Schiller, and B. Bonavida
Adriamycin Sensitizes the Adriamycin-resistant 8226/Dox40 Human Multiple Myeloma Cells to Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated (TRAIL) Apoptosis
Clin. Cancer Res., December 1, 2001; 7(12): 3874 - 3883.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. J. Lum, A. A. Pilon, J. Sanchez-Dardon, B. N. Phenix, J. E. Kim, J. Mihowich, K. Jamison, N. Hawley-Foss, D. H. Lynch, and A. D. Badley
Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L
J. Virol., November 15, 2001; 75(22): 11128 - 11136.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. D. Zhang, X. Y. Zhang, C. P. Gray, T. Nguyen, and P. Hersey
Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Human Melanoma Is Regulated by Smac/DIABLO Release from Mitochondria
Cancer Res., October 1, 2001; 61(19): 7339 - 7348.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Di Pietro, P. Secchiero, R. Rana, D. Gibellini, G. Visani, K. Bemis, L. Zamai, S. Miscia, and G. Zauli
Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1
Blood, May 1, 2001; 97(9): 2596 - 2603.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kagawa, C. He, J. Gu, P. Koch, S.-J. Rha, J. A. Roth, S. A. Curley, L. C. Stephens, and B. Fang
Antitumor Activity and Bystander Effects of the Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Gene
Cancer Res., April 1, 2001; 61(8): 3330 - 3338.
[Abstract] [Full Text]

Home page
 JEMHome page
M. J. Smyth, E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon {gamma}-Dependent Natural Killer Cell Protection from Tumor Metastasis
J. Exp. Med., March 19, 2001; 193(6): 661 - 670.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Mitsiades, V. Poulaki, C. Mitsiades, and M. Tsokos
Ewing's Sarcoma Family Tumors Are Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Express Death Receptor 4 and Death Receptor 5
Cancer Res., March 1, 2001; 61(6): 2704 - 2712.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. Nimmanapalli, C. L. Perkins, M. Orlando, E. O’Bryan, D. Nguyen, and K. N. Bhalla
Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels
Cancer Res., January 1, 2001; 61(2): 759 - 763.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S.-Y. Sun, P. Yue, W. K. Hong, and R. Lotan
Augmentation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by the Synthetic Retinoid 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) through Up-Regulation of TRAIL Receptors in Human Lung Cancer Cells
Cancer Res., December 1, 2000; 60(24): 7149 - 7155.
[Abstract] [Full Text]

Home page
 BloodHome page
J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington, and K. Bhalla
Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
Blood, December 1, 2000; 96(12): 3900 - 3906.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. S. Griffith, R. D. Anderson, B. L. Davidson, R. D. Williams, and T. L. Ratliff
Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis
J. Immunol., September 1, 2000; 165(5): 2886 - 2894.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.